theory clinical_64_8
imports Main

begin

typedecl entity
typedecl event

consts
  KinaseInhibitor :: "entity ⇒ bool"
  Mutations :: "entity ⇒ bool"
  PI3KAKTPathway :: "entity ⇒ bool"
  Target :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  In :: "entity ⇒ entity ⇒ bool"
  Inhibit :: "event ⇒ bool"
  Proliferation :: "entity ⇒ bool"
  Survival :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  AlpelisibFulvestrant :: "entity ⇒ bool"
  PIK3CAMutation :: "entity ⇒ bool"
  Directly :: "event ⇒ bool"
  Beneficial :: "event ⇒ bool"
  Patients :: "entity ⇒ bool"
  PIK3CAMutated :: "entity ⇒ bool"
  HRPositive :: "entity ⇒ bool"
  HER2Negative :: "entity ⇒ bool"
  AdvancedBreastCancer :: "entity ⇒ bool"
  EndocrineTherapy :: "entity ⇒ bool"
  Received :: "event ⇒ bool"
  Previously :: "event ⇒ bool"
  Prolongs :: "event ⇒ bool"
  ProgressionFreeSurvival :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  From :: "event ⇒ entity ⇒ bool"
  Improve :: "event ⇒ bool"
  Outcomes :: "entity ⇒ bool"
  PatientEntity :: "entity ⇒ bool"
  Chemotherapy :: "entity ⇒ bool"
  LessSensitive :: "entity ⇒ entity ⇒ bool"

(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)
axiomatization where
  explanation_1: "∃x y z e1 e2. KinaseInhibitor x ∧ Mutations y ∧ PI3KAKTPathway z ∧ Target e1 ∧ Agent e1 x ∧ Patient e1 y ∧ In y z ∧ Inhibit e2 ∧ Agent e2 x ∧ Proliferation y ∧ Survival y"

(* Explanation 2: Treatment with alpelisib–fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)
axiomatization where
  explanation_2: "∃x y z w e1 e2 e3. Treatment x ∧ AlpelisibFulvestrant x ∧ PIK3CAMutation y ∧ Target e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Directly e1 ∧ Beneficial e2 ∧ Patients z ∧ PIK3CAMutated z ∧ HRPositive z ∧ HER2Negative z ∧ AdvancedBreastCancer z ∧ EndocrineTherapy w ∧ Received e3 ∧ Agent e3 z ∧ Patient e3 w ∧ Previously e3 ∧ Prolongs e2 ∧ ProgressionFreeSurvival y"

(* Explanation 3: Patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation and improves outcomes. *)
axiomatization where
  explanation_3: "∃x y z w e1 e2 e3 e4. Patients x ∧ EndocrineTherapy y ∧ PIK3CAMutated x ∧ HRPositive x ∧ HER2Negative x ∧ AdvancedBreastCancer x ∧ Received e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Previously e1 ∧ Benefit e2 ∧ Treatment z ∧ AlpelisibFulvestrant z ∧ From e2 z ∧ PIK3CAMutation w ∧ Target e3 ∧ Agent e3 z ∧ Patient e3 w ∧ Improve e4 ∧ Agent e4 z ∧ Outcomes w"

(* Explanation 4: Patient is likely less sensitive to chemotherapy. *)
axiomatization where
  explanation_4: "∀x y. PatientEntity x ∧ Chemotherapy y ⟶ LessSensitive x y"

theorem hypothesis:
  assumes asm: "PatientEntity x ∧ EndocrineTherapy y ∧ Received e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Previously e1"
  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)
  shows "(∀x y z e1 e2. PatientEntity x ∧ EndocrineTherapy y ∧ Received e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Previously e1 ⟶ (Benefit e2 ∧ Agent e2 x ∧ Treatment z ∧ AlpelisibFulvestrant z ∧ From e2 z ∧ Target e2 ∧ PIK3CAMutation z))"
proof -
  (* From the premise, we have information about the patient entity and their previous endocrine therapy. *)
  from asm have "PatientEntity x ∧ EndocrineTherapy y ∧ Received e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Previously e1" by meson
  (* Explanation 3 states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant. *)
  (* This aligns with the logical relation Implies(H, I), where H is the condition of having previously received endocrine therapy and having PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, and I is the benefit from treatment with alpelisib-fulvestrant. *)
  (* Since the premise matches the condition H, we can infer the benefit I. *)
  then have "Benefit e2 ∧ Agent e2 x ∧ Treatment z ∧ AlpelisibFulvestrant z ∧ From e2 z ∧ Target e2 ∧ PIK3CAMutation z" sledgehammer
  then show ?thesis <ATP>
qed

end
